Explore 3 Stock Ideas & Industry Insights Download Free Report

Bionano Genomics Inc

Healthcare US BNGO

1.17USD
-0.09(7.14%)

Last update at 2026-06-05T20:00:00Z

Day Range

1.171.26
LowHigh

52 Week Range

1.065.50
LowHigh

Fundamentals

  • Previous Close 1.26
  • Market Cap13.98M
  • Volume208419
  • P/E Ratio-
  • Dividend Yield-%
  • EBITDA-23.81200M
  • Revenue TTM28.51M
  • Revenue Per Share TTM5.24
  • Gross Profit TTM 13.19M
  • Diluted EPS TTM-4.85

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Financials

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Income before tax -26.32800M -111.98400M -232.43100M -130.71200M -78.15200M
Minority interest - - - - -
Net income -26.39500M -112.01700M -232.49300M -132.59600M -72.43500M
Selling general administrative 35.15M 51.85M 93.50M 88.60M 58.49M
Selling and marketing expenses - - - - -
Gross profit 6.26M 0.38M 9.57M 5.95M 3.87M
Reconciled depreciation 9.73M 14.23M 13.91M 9.84M 3.37M
Ebit -33.33900M -111.69500M -227.31200M -131.69800M -77.10100M
Ebitda -23.60800M -97.46900M -213.60400M -130.41400M -76.92400M
Depreciation and amortization 9.73M 14.23M 13.71M 1.28M 0.18M
Non operating income net other - - - -0.22300M -0.36000M
Operating income -33.33900M -103.98300M -215.24500M -131.69800M -77.10100M
Other operating expenses 61.85M 134.76M 251.36M 159.50M 95.08M
Interest expense 0.30M 0.29M 5.12M 0.30M 0.93M
Tax provision 0.07M 0.03M 0.06M 1.88M -5.71700M
Interest income 4.89M 2.10M 3.31M 1.51M 0.24M
Net interest income 4.60M -1.82500M -1.80800M 1.21M -0.69100M
Extraordinary items - - - - -
Non recurring - - - - -
Other items - - - - -
Income tax expense 0.07M 0.03M 0.06M 1.88M -5.71700M
Total revenue 28.51M 30.78M 36.12M 27.80M 17.98M
Total operating expenses 39.60M 104.36M 224.81M 137.64M 80.97M
Cost of revenue 22.25M 30.40M 26.55M 21.86M 14.11M
Total other income expense net 7.01M -8.00100M -17.18600M 0.99M -1.05100M
Discontinued operations - - - - -
Net income from continuing ops -26.39500M -112.01700M -232.49300M -132.59600M -72.43500M
Net income applicable to common shares - - - -132.59600M -72.43500M
Preferred stock and other adjustments - - - - -
Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Total assets 73.58M 76.67M 214.40M 307.50M 377.10M
Intangible assets 4.34M 9.71M 33.97M 41.14M 26.84M
Earning assets - - - - -
Other current assets 21.48M 14.12M 5.68M 7.33M 4.48M
Total liab 29.16M 41.30M 118.25M 58.10M 39.98M
Total stockholder equity 44.42M 35.38M 96.16M 249.40M 337.12M
Deferred long term liab - - - 0.13M 0.15M
Other current liab 16.41M 4.91M 8.09M 19.93M 9.69M
Common stock 0.00100M - 0.00500M 0.03M 0.03M
Capital stock 0.00100M 0.00000M 0.00500M 0.03M 0.03M
Retained earnings -719.62000M -693.22500M -581.20800M -348.71500M -216.11900M
Other liab - - - 13.10M 9.21M
Good will - - 0.00000M 77.29M 56.16M
Other assets - - - 2.81M 0.75M
Cash 2.99M 9.17M 53.06M 5.09M 24.57M
Cash and equivalents - - - - -
Total current liabilities 22.94M 37.34M 100.03M 35.88M 21.84M
Current deferred revenue - 1.13M 0.78M 0.87M 0.68M
Net debt 3.92M 18.12M 34.88M 6.58M -13.87500M
Short term debt 0.95M 23.61M 80.77M 2.54M 1.77M
Short long term debt - - 69.80M - -
Short long term debt total 6.92M 27.30M 87.95M 11.67M 10.70M
Other stockholder equity 764.03M 728.57M 677.34M 599.21M 553.75M
Property plant equipment - - - 18.03M 10.32M
Total current assets 45.39M 39.49M 140.12M 157.30M 272.41M
Long term investments - - - - -
Net tangible assets - - - 172.11M 337.12M
Short term investments 10.27M 0.30M 48.82M 108.09M 226.04M
Net receivables 5.20M 4.77M 9.66M 7.02M 4.93M
Long term debt - - - - -
Inventory 5.45M 11.12M 22.89M 29.76M 12.39M
Accounts payable 5.59M 6.96M 10.38M 12.53M 9.70M
Total permanent equity - - - - -
Noncontrolling interest in consolidated entity - - - - -
Temporary equity redeemable noncontrolling interests - - - - -
Accumulated other comprehensive income 0.02M 0.03M 0.02M -1.12400M -0.53900M
Additional paid in capital - - - - -
Common stock total equity - - - 0.03M 0.03M
Preferred stock total equity - - - - -
Retained earnings total equity - - - -348.71500M -216.11900M
Treasury stock - - - - -
Accumulated amortization - - - - -
Non currrent assets other 2.69M 3.15M 7.43M 2.81M 0.75M
Deferred long term asset charges - - - - -
Non current assets total 28.20M 37.18M 74.29M 150.20M 104.69M
Capital lease obligations 6.92M 6.93M 9.61M 11.67M 10.70M
Long term debt total - - - - -
Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Investments -12.74700M 73.84M 24.16M 116.69M -226.90900M
Change to liabilities - - - 2.31M 10.74M
Total cashflows from investing activities -12.74700M 73.84M 24.16M 82.77M -278.06200M
Net borrowings -4.94600M -48.05800M 70.95M -0.03600M -15.00000M
Total cash from financing activities 24.04M -13.68500M 113.81M 23.01M 336.11M
Change to operating activities - - - -3.96100M 1.99M
Net income -26.39500M -112.01700M -232.49300M -132.59600M -72.43500M
Change in cash -5.06400M -8.77500M 12.86M -19.08000M -13.87800M
Begin period cash flow 9.57M 18.35M 5.49M 24.57M 38.45M
End period cash flow 4.51M 9.57M 18.35M 5.49M 24.57M
Total cash from operating activities -16.34500M -68.92200M -125.18100M -124.81600M -71.92700M
Issuance of capital stock 31.10M 44.43M 57.70M 23.13M 342.71M
Depreciation 9.73M 14.23M 13.91M 9.84M 3.37M
Other cashflows from investing activities - - - -33.13400M -50.51500M
Dividends paid - - - - -
Change to inventory 4.92M -0.58700M -4.15000M -23.67600M -15.92800M
Change to account receivables -0.44800M 4.14M -2.29600M -2.90000M -0.49300M
Sale purchase of stock - - - 22.89M 351.03M
Other cashflows from financing activities 24.04M -10.06000M -14.83500M -0.08500M 8.40M
Change to netincome - - - 25.21M 4.21M
Capital expenditures 0.00000M 0.10M 1.69M 3.30M 1.46M
Change receivables - - - -2.90000M -0.49300M
Cash flows other operating - - - -3.42600M -1.70400M
Exchange rate changes - - - - -
Cash and cash equivalents changes - - - -19.04200M -13.87800M
Change in working capital 0.51M 4.40M -14.77000M -28.58800M -7.65200M
Stock based compensation 4.53M 9.74M 15.18M 22.42M 9.72M
Other non cash items -4.72900M 14.73M 92.99M 2.35M 0.85M
Free cash flow -16.34500M -69.02500M -126.87200M -128.11800M -73.38700M

Peer Comparison

Sector: Healthcare Industry: Medical Instruments & Supplies

Company Change (USD) Price (USD) Trailing PE (x) Forward PE (x) Price Sales TTM (x) Price to Book Value (x) Enterprise Value to Revenue (x) Enterprise Value to EBITDA (x)
BNGO
Bionano Genomics Inc
-0.09 7.14% 1.17 - - 0.49 0.33 0.08 -0.1752
ISRG
Intuitive Surgical Inc
3.24 0.77% 422.06 73.05 61.73 19.15 10.25 18.41 59.92
ESLOF
EssilorLuxottica Société anonyme
-5.1675 2.52% 200.15 44.84 27.62 4.07 2.49 3.71 16.04
ESLOY
Essilor International SA
-3.16 3.08% 99.50 41.68 27.25 3.94 2.45 3.71 16.04
BDX
Becton Dickinson and Company
1.60 1.07% 151.16 25.56 12.48 2.59 1.76 2.89 12.55

Reports Covered

Stock Research & News

Profile

Bionano Genomics, Inc., together with its subsidiaries, provides genome analysis solutions in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. The company offers genome analysis software that enables genomics labs to analyze and interpret data across a range of platforms to generate informative data visualizations for streamlined and simple reporting of causal variants. It also provides Saphyr and Stratys systems, which are sample-to-result solutions for structural variation analysis by optical genome mapping for genome analysis and understanding of genetic variation and function; Saphyr and Stratys instruments, which are single-molecule imagers; Saphyr Chip, a consumable that packages the nanochannel arrays for DNA linearization; Bionano Prep Kits and DNA labeling kits, which provide the reagents and protocols for extracting and labeling ultra-high molecular weight DNA; and Ionic purification system, which isolates and purifies nucleic acid molecules. In addition, the company offers Saphyr, Stratys, and Bionano compute servers; and VIA software, which offers one solution for analysis and interpretation of genomic data from microarray and sequencing data for cytogenetics and molecular genetics. Further, it provides testing and laboratory services comprising FirstStepDx PLUS, a chromosomal microarray for identifying an underlying genetic cause in individuals with autism spectrum disorder, developmental delay, and intellectual disability; Fragile X syndrome (FXS) testing services; NextStepDx PLUS, a exome sequencing test to identify genetic variants that are associated with disorders of childhood development; OGM-Dx HemeOne testing; OGM-Dx FSHD, a test for individuals suspected of having FSHD type 1; and OGM-Dx Postnatal Whole Genome SV and OGM-Dx Prenatal Whole Genome SV for comprehensive testing. Bionano Genomics, Inc. was founded in 2003 and is headquartered in San Diego, California.

Bionano Genomics Inc

9540 Towne Centre Drive, San Diego, CA, United States, 92121

Key Executives

Name Title Year Born
Dr. Robert Erik Holmlin M.B.A., Ph.D. Pres, CEO, Sec. & Director 1968
Mr. Mark Oldakowski Chief Operating Officer 1974
Mr. Christopher P. Stewart Chief Financial Officer 1970
Mr. Mark Adamchak CPA VP of Accounting & Controller NA
Jonathan Dixon Global Head of Legal NA
Mr. Stanislas Marin M.B.A., M.S. Head of Global Sales NA
Ms. Helene Klein Chief People Officer NA
Dr. Alka Chaubey FACMG, Ph.D. Chief Medical Officer 1973
Dr. Soheil Shams Ph.D. CIO of Emeritus 1964
Ms. Donna Polizio Global Head of Market Access NA

Disclaimer - This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.

We use cookies to help us improve, promote, and protect our services. By continuing to use this site, we assume you consent to our Cookies Policy. For more information, read our Privacy Policy and Terms and Conditions